The ultra-high risk concept - A review

Canadian Journal of Psychiatry

Volumn 58, Issue 1, 2013, Pages 5-12

  Yung, Alison R ^a,b   Nelson, Barnaby ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Clinical high risk; Early psychosis; High risk; Prodrome; Psychosis; Schizophrenia; Ultra high risk

Indexed keywords

OLANZAPINE; OMEGA 3 FATTY ACID; RISPERIDONE;

ATTENTION; COGNITION; COGNITIVE THERAPY; CONCEPT ANALYSIS; DISEASE CLASSIFICATION; DISEASE DURATION; DISEASE SEVERITY; FALSE POSITIVE RESULT; FOLLOW UP; GENETIC RISK; HEALTH SERVICE; HIGH RISK PATIENT; HUMAN; MENTAL HEALTH; META ANALYSIS (TOPIC); NEGATIVE SYNDROME; NEUROPROTECTION; OUTCOME ASSESSMENT; PERCEPTION; PRODROMAL SYMPTOM; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SCHIZOPHRENIA; ULTRA HIGH RISK;

EID: 84873052967     PISSN: 07067437     EISSN: 14970015     Source Type: Journal    
DOI: 10.1177/070674371305800103     Document Type: Review

References (103)

1. Murray CJ, Lopez AD, Mathers CD, et al. The global burden of disease 2000 project: aims, methods and data sources. Cambridge (MA): Harvard Burden of Disease Unit; 2001.
2. American Psychiatric Association (APA). Diagnostic and statistical manual of mental disorders. Washington (DC): APA; 1994.
3. Yung AR, McGorry PD. The prodromal phase of first-episode psychosis: past and current conceptualizations. Schizophr Bull. 1996;22(2):353-370.
4. Robinson DG, Woerner MG, McMeniman M, et al. Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry. 2004;161(3):473-479.
5. Sullivan HS. The onset of schizophrenia. Am J Psychiatry. 1994;151(6):135-139.
6. Meares A. The diagnosis of prepsychotic schizophrenia. Lancet. 1959;1(7063):55-58.
7. Post SG. Preventing schizophrenia and Alzheimer disease: comparative ethics. Schizophr Res. 2001;51(1):103-108.
8. Beiser M, Erickson D, Fleming JA, et al. Establishing the onset of psychotic illness. Am J Psychiatry. 1993;150(9):1349-1354.
9. Olsen KA, Rosenbaum B. Prospective investigations of the prodromal state of schizophrenia: review of studies. Acta Psychiatr Scand. 2006;113:247-272.
10. Huber G, Gross G. The concept of basic symptoms in schizophrenic and schizoaffective psychoses. Recenti Prog Med. 1989;80(12):646-652.
11. Riecher A, Maurer K, Loffler W, et al. Schizophrenia-a disease of young single males? Preliminary results from an investigation on a representative cohort admitted to hospital for the first time. Eur Arch Psychiatry Neurol Sci. 1989;239(3):210-212.
12. Häfner H, Riecher-Rossler A, Hambrecht M, et al. IRAOS: an instrument for the assessment of onset and early course of schizophrenia. Schizophr Res. 1992;6(3):209-223.
13. Häfner H, Maurer K, Löffler W, et al. The ABC Schizophrenia Study: a preliminary overview of the results. Soc Psychiatry Psychiatr Epidemiol. 1998;33(8):380-386.
14. Häfner H, Maurer K, Löffler W, et al. The influence of age and sex on the onset and early course of schizophrenia. Br J Psychiatry. 1993;162:80-86.
15. Häfner H, Riecher-Rossler A, Maurer K, et al. First onset and early symptomatology of schizophrenia. A chapter of epidemiological and neurobiological research into age and sex differences. Eur Arch Psychiatry Clin Neurosci. 1992;242(2-3):109-118.
16. Falloon IRH. Early intervention for first episodes of schizophrenia: a preliminary exploration. Psychiatry. 1992;55:4-15.
17. Falloon IRH. General practice recruitment for people at risk of schizophrenia: the Buckingham experience. Aust N Z J Psychiatry. 2000;34(Suppl):S131-S136; discussion S140-S144.
18. Lieberman JA, Perkins D, Belger A, et al. The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol Psychiatry. 2001;50:884-897.
19. Häfner H, Maurer K, Trendler G, et al. Schizophrenia and depression: challenging the paradigm of two separate diseases-a controlled study of schizophrenia, depression and healthy controls. Schizophr Res. 2005;77(1):11-24.
20. Häfner H, Riecher-Rossler A, An Der Heiden W, et al. Generating and testing a causal explanation of the gender difference in age at first onset of schizophrenia. Psychol Med. 1993;23(4):925-940.
21. Yung AR, Phillips LJ, McGorry PD. Treating schizophrenia in the prodromal phase. London (GB): Taylor & Francis; 2004.
22. Yung AR, Phillips LJ, Yuen HP, et al. Psychosis prediction: 12-month follow up of a high-risk ("prodromal") group. Schizophr Res. 2003;60(1):21-32.
23. Yung AR, Phillips LJ, Yuen HP, et al. Risk factors for psychosis in an ultra high-risk group: psychopathology and clinical features. Schizophr Res. 2004;67(2-3):131-142.
24. Cornblatt B, Lencz T, Obuchowski M. The schizophrenia prodrome: treatment and high-risk perspectives. Schizophr Res. 2002;54(1-2):177-186.
25. Yung AR, McGorry PD, McFarlane CA, et al. Monitoring and care of young people at incipient risk of psychosis. Schizophr Bull. 1996;22(2):283-303.
26. Broome MR, Woolley JB, Johns LC, et al. Outreach and Support in South London (OASIS): implementation of a clinical service for prodromal psychosis and the at risk mental state. Eur Psychiatry. 2005;20(5-6):372-378.
27. Miller T, McGlashan TH, Rosen J, et al. Prospective diagnosis of the initial prodrome for schizophrenia based on the structured interview for prodromal syndromes: preliminary evidence of interrater reliability and predictive validity. Am J Psychiatry. 2002;159(5):863-865.
28. Miller TJ, McGlashan TH, Rosen JL, et al. Prodromal assessment with the Structured Interview for Prodromal Syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability. Schizophr Bull. 2003;29(4):703-715.
29. Yung A, Yuen H, McGorry P, et al. Mapping the onset of psychosis: the Comprehensive Assessment of At-Risk Mental States. Aust N Z J Psychiatry. 2005;39:964-971.
30. Miller TJ, McGlashan TH, Rosen JL, et al. Prospective diagnosis of the initial prodrome for schizophrenia based on the Structured Interview for Prodromal Syndromes: preliminary evidence of interrater reliability and predictive validity. Am J Psychiatry. 2002;159(5):863-865.
31. Schultze-Lutter F. Subjective symptoms of schizophrenia in research and the clinic: the basic symptom concept. Schizophr Bull. 2009;35(1):5-8.
32. Klosterkötter J, Hellmich M, Steinmeyer EM, et al. Diagnosing schizophrenia in the initial prodromal phase. Arch Gen Psychiatry. 2001;58:158-164.
33. Klosterkötter J, Gross G, Huber G, et al. Evaluation of the Bonn Scale for the Assessment of Basic Symptoms-BSABS as an instrument for the assessment of schizophrenia proneness: a review of recent findings. Neurol Psychiatry Brain Res. 1997;5:137-150.
34. Schultze-Lutter F, Addington J, Ruhrmann S, et al. Schizophrenia Proneness Instrument, Adult version (SPI-A). Rome (IT): Giovanni Fiorito Editore; 2007.
35. Mason O, Startup M, Halpin S, et al. Risk factors for transition to first episode psychosis among individuals with 'at-risk mental states.' Schizophr Res. 2004;71(2-3):227-237.
36. Cannon TD, Cadenhead K, Cornblatt B, et al. Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch Gen Psychiatry. 2008;65(1):28-37.
37. Ruhrmann S, Schultze-Lutter F, Klosterkötter J. Early detection and intervention in the initial prodromal phase of schizophrenia. Pharmacopsychiatry. 2003;36(Suppl):S162-S167.
38. Fusar-Poli P, Bonoldi I, Yung AR, et al. Predicting psychosis: metaanalysis of evidence of transition outcomes in individuals at high clinical risk. Arch Gen Psychiatry. 2012;69:220-229.
39. Keshavan MS, DeLisi LE, Seidman LJ. Early and broadly defined psychosis risk mental states. Schizophr Res. 2011;126(1-3):1-10.
40. Klosterkötter J, Schultze-Lutter F, Bechdolf A, et al. Prediction and prevention of schizophrenia: what has been achieved and where to go next? World Psychiatry. 2011;10(3):165-174.
41. Ruhrmann S, Schultze-Lutter F, Salokangas RK, et al. Prediction of psychosis in adolescents and young adults at high risk: results from the prospective European prediction of psychosis study. Arch Gen Psychiatry. 2010;67(3):241-251.
42. Simon AE, Dvorsky DN, Boesch J, et al. Defining subjects at risk for psychosis: a comparison of two approaches. Schizophr Res. 2006;81:83-90.
43. Yung AR, Yuen HP, McGorry PD, et al. Mapping the onset of psychosis: the Comprehensive Assessment of At-Risk Mental States. Aust N Z J Psychiatry. 2005;39(11-12):964-971.
44. Haroun N, Dunn L, Haroun A, et al. Risk and protection in prodromal schizophrenia: ethical implications for clinical practice and future research. Schizophr Bull. 2006;32:166-178.
45. Johnstone EC, Ebmeier KP, Miller P, et al. Predicting schizophrenia: findings from the Edinburgh High-Risk Study. Br J Psychiatry. 2005;186(1):18-25.
46. Yung AR, Stanford C, Cosgrave E, et al. Testing the ultra high risk (prodromal) criteria for the prediction of psychosis in a clinical sample of young people. Schizophr Res. 2006;84:57-66.
47. Cannon TD, Cadenhead K, Cornblatt B, et al. Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch Gen Psychiatry. 2008;65(1):28-37.
48. Thompson A, Nelson B, Yung AR. Predictive validity of clinical variables in the "at risk" for psychosis population: international comparison with results from the North American Prodromal Longitudinal Study. Schizophr Res. 2011;126:51-57.
49. McGlashan TH, Zipursky RB, Perkins D, et al. Randomized, doubleblind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry. 2006;163(5):790-799.
50. McGorry PD, Yung AR, Phillips LJ, et al. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry. 2002;59:921-928.
51. Morrison AP, French P, Walford L, et al. Cognitive therapy for the prevention of psychosis in people at ultra-high risk: randomised controlled trial. Br J Psychiatry. 2004;185(4):291-297.
52. Amminger GP, Schäfer M, Papageorgiou K, et al. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch Gen Psychiatry. 2010;67(2):146-154.
53. Yung AR, Phillips LJ, Nelson B, et al. Randomized controlled trial of interventions for young people at ultra high risk of psychosis: 6 month analysis. J Clin Psychiatry. 2011;72(4):430-440.
54. Phillips LJ, McGorry PD, Yuen HP, et al. Medium term follow-up of a randomized controlled trial of interventions for young people at ultra high risk of psychosis. Schizophr Res. 2007;96:25-33.
55. Morrison AP, French P, Parker S, et al. Three-year follow-up of a randomized controlled trial of cognitive therapy for the prevention of psychosis in people at ultra high risk. Schizophr Bull. 2007;33(3):682-687.
56. Addington J, Epstein I, Liu L, et al. A randomized controlled trial of cognitive behavioral therapy for individuals at clinical high risk of psychosis. Schizophr Res. 2011;125:54-61.
57. McGorry PD, Killackey E, Yung AR. Early intervention in psychosis: concepts, evidence and future directions. World Psychiatry. 2008;7(3):148-156.
58. Nordentoft M, Thorup A, Petersen L, et al. Transition rates from schizotypal disorder to psychotic disorder for first-contact patients included in the OPUS trial. A randomized clinical trial of integrated treatment and standard treatment. Schizophr Res. 2006;83(1):29-40.
59. Bechdolf A, Wagner M, Veith V, et al. Randomized controlled multicentre trial of cognitive behaviour therapy in the early initial prodromal state: effects on social adjustment post treatment. Early Interv Psychiatry. 2007;1(1):71-78.
60. Bechdolf A, Wagner M, Veith V, et al. A randomized controlled multicenter trial of cogntive behavioural therapy in the early initial prodromal state of psychosis. Schizophr Res. 2008;86:S8.
61. Preti A, Cella M. Randomized-controlled trials in people at ultra high risk of psychosis: a review of treatment effectiveness. Schizophr Res. 2010;123(1):30-36.
62. National Early Psychosis Clinical Guidelines Working Party. Australian clinical guidelines for early psychosis. 2nd ed. Melbourne (AU): Orygen Youth Health Research Centre; 2010.
63. Addington J, Amminger GP, et al. International clinical practice guidelines for early psychosis. Br J Psychiatry. 2005;187(Suppl 48):120-124.
64. McGorry PD, Killackey E, Yung AR. Early intervention in psychotic disorders: detection and treatment of the first episode and the critical early stages. Med J Aust. 2007;187(7 Suppl):S8-S10.
65. Yung AR, Nelson B, Stanford C, et al. Validation of "prodromal" criteria to detect individuals at ultra high risk of psychosis: 2 year follow up. Schizophr Res. 2008;105:10-17.
66. Ruhrmann S, Schultze-Lutter F, Salokangas RKR, et al. Prediction of psychosis in adolescents and young adults at high risk: results from the prospective European Prediction of Psychosis Study. Arch Gen Psychiatry. 2010;67(3):241-251.
67. Demjaha A, Valmaggia L, Stahl D, et al. Disorganization/cognitive and negative symptom dimensions in the at-risk mental state predict subsequent transition to psychosis. Schizophr Bull. 2012;38(2):351-359.
68. Simon AE, Umbricht D. High remission rates from an initial ultra-high risk state for psychosis. Schizophr Res. 2010;116:168-172.
69. Lemos-Giráldez S, Vallina-Fernández O, Fernández- Iglesias P, et al. Symptomatic and functional outcome in youth at ultrahigh risk for psychosis: a longitudinal study. Schizophr Res. 2009;115(2-3):121-129.
70. Carpenter WT. Anticipating DSM-V: should psychosis risk become a diagnostic class? Schizophr Bull. 2009;35(5):841-843.
71. van Os J, Linscott RJ, Myin-Germeys I, et al. A systematic review and meta-analysis of the psychosis continuum: evidence for a psychosis proneness-persistence-impairment model of psychotic disorder. Psychol Med. 2009;39(2):179-195.
72. Fusar-Poli P, Borgwardt S. Integrating the negative psychotic symptoms in the high risk criteria for the prediction of psychosis. Med Hypotheses. 2007;69(4):959-960.
73. Velthorst E, Nieman D, Linszen D, et al. Disability in people clinically at high risk of psychosis. Br J Psychiatry. 2010;197:278-284.
74. Cornblatt BA, Auther AM, Niendam T, et al. Preliminary findings for two new measures of social and role functioning in the prodromal phase of schizophrenia. Schizophr Bull. 2007;33(3):688-702.
75. Brewer WJ, Wood SJ, Phillips LJ, et al. Generalised and specific cognitive performance in clinical high-risk cohorts: a review highlighting potential vulnerability markers for psychosis. Schizophr Bull. 2006;32:538-555.
76. Yung AR, Nelson B, Thompson A, et al. The psychosis threshold in ultra high risk (prodromal) research: is it valid? Schizophr Res. 2010;120(1-3):1-6.
77. Addington J, Cornblatt BA, Cadenhead KS, et al. At clinical high risk for psychosis: outcome for nonconverters. Am J Psychiatry. 2011;168(8):800-805.
78. Linscott RJ, van Os J. Systematic reviews of categorical versus continuum models in psychosis: evidence for discontinuous subpopulations underlying a psychometric continuum. Implications for DSM-V, DSM-VI, and DSM-VII. Annu Rev Clin Psychol. 2010;6:391-419.
79. van Os J, Linscott RJ. Introduction: the extended psychosis phenotype-relationship with schizophrenia and with ultrahigh risk status for psychosis. Schizophr Bull. 2012;38(2):227-230.
80. Hanssen M, Bak M, Bijl R, et al. The incidence and outcome of subclinical psychotic experiences in the general population. Br J Clin Psychol. 2005;44(2):181-191.
81. Wiles NJ, Zammit S, Bebbington P, et al. Self-reported psychotic symptoms in the general population: results from the longitudinal study of the British National Psychiatric Morbidity Survey. Br J Psychiatry. 2006;188:519-526.
82. Kaymaz N, Drukker M, Lieb R, et al. Do subthreshold psychotic experiences predict clinical outcomes in unselected non-helpseeking population-based samples? A systematic review and metaanalysis, enriched with new results. Psychol Med. 2012 Jan 20:1-15; Epub ahead of print.
83. Yung AR, Nelson B, Baker K, et al. Psychotic-like experiences in a community sample of adolescents: implications for the continuum model of psychosis and prediction of schizophrenia. Aust N Z J Psychiatry. 2009;43(2):118-128.
84. Schimmelmann BG, Michel C, Schaffner N, et al. What percentage of people in the general population satisfies the current clinical at-risk criteria of psychosis? Schizophr Res. 2011;125(1):99-100.
85. Kelleher I, Murtagh A, Molloy C, et al. Identification and characterization of prodromal risk syndromes in young adolescents in the community: a population-based clinical interview study. Schizophr Bull. 2012;38:239-246.
86. Kelleher I, Connor D, Clarke MC, et al. Prevalence of psychotic symptoms in childhood and adolescence: a systematic review and meta-analysis of population-based studies. Psychol Med. 2012;42(9):1857-1863.
87. Yung AR. The schizophrenia prodrome: a high risk concept. Schizophr Bull. 2003;29(4):857-863.
88. Nelson B, Yung AR. Psychotic-like experiences as overdetermined phenomena: when do they increase risk for psychotic disorder? Schizophr Res. 2009;108(1-3):303-304.
89. Corcoran CM, First MB, Cornblatt B. The psychosis risk syndrome and its proposed inclusion in the DSM-V: a risk-benefit analysis. Schizophr Res. 2010;120(1-3):16-22.
90. Johannessen JO, McGorry P. DSM-5 and the "Psychosis Risk Syndrome": the need for a broader perspective. Psychosis: Psychological, Social and Integrative Approaches. 2010;2(2):93-96.
91. McGorry PD. Risk syndromes, clinical staging and DSM V: new diagnostic infrastructure for early intervention in psychiatry. Schizophr Res. 2010;120(1-3):49-53.
92. Morrison AP, Byrne R, Bentall RP. DSM-5 and the "Psychosis Risk Syndrome": whose best interests would it serve? Psychosis: Psychological, Social and Integrative Approaches. 2010;2(2):96-99.
93. Nelson B, Yung AR. Should a risk syndrome for first episode psychosis be included in the DSM V? Curr Opin Psychiatry. 2011;24:128-133.
94. Woods SW, Walsh BC, Saksa JR, et al. The case for including attenuated psychotic symptoms syndrome in DSM-5 as a psychosis risk syndrome. Schizophr Res. 2010;123(2-3):199-207.
95. Yang LH, Wonpat-Borja AJ, Opler MG, et al. Potential stigma associated with inclusion of the psychosis risk syndrome in the DSM-V: an empirical question. Schizophr Res. 2010;120(1-3):42-48.
96. Yung AR, Nelson B, Thompson AD, et al. Should a "Risk Syndrome for Psychosis" be included in the DSMV? Schizophr Res. 2010;120:7-15.
97. Woods SW, Addington J, Cadenhead KS, et al. Validity of the prodromal risk syndrome for first psychosis: findings from the North American Prodrome Longitudinal Study. Schizophr Bull. 2009;35(5):894-908.
98. American Psychiatric Association (APA) DSM-5 Development. Attenuated psychosis syndrome (proposed for section III of the DSM-5) [Internet]. Arlington (VA): APA; 2012 [date cited unknown]. Available from: http://www.dsm5.org/ ProposedRevisions/Pages/proposedrevision.aspx?rid=412#.
99. Ross CA. DSM-5 and the "Psychosis Risk Syndrome": eight reasons to reject it. Psychosis: Psychological, Social and Integrative Approaches. 2010;2(2):107-110.
100. Cooper R. What is wrong with the DSM? Hist Psychiatry. 2004;15(1):5-25.
101. Yung AR. Risk, disorder and diagnosis. Aust N Z J Psychiatry. 2011;45(11):915-919.
102. Fusar-Poli P, Yung AR. Should attenuated psychosis syndrome be included in the DSM5? The debate. Lancet. 2012;379(9816):591-592.
103. Nelson B, Yung AR. Should a risk syndrome for first episode psychosis be included in DSMV? Curr Opin Psychiatry. 2011;24(2):128-133.